Antibody immunotherapy for leukemia Journal Article


Author: Jurcic, J. G.
Article Title: Antibody immunotherapy for leukemia
Abstract: Monoclonal antibodies have become an important modality for cancer therapy. Genetically engineered chimeric and humanized antibodies have demonstrated activity against both overt leukemia and minimal residual disease. High-dose radioimmunotherapy can potentially allow intensification of antileukemic therapy before bone marrow transplantation yet minimize radiation exposure to normal organs. Targeted alpha particle therapy offers the possibility of selective tumor cell kill while sparing surrounding normal cells. Antibody-drug conjugates and immunotoxins have produced complete remissions in leukemia.
Keywords: survival; treatment outcome; survival analysis; clinical trial; mortality; review; methodology; controlled clinical trial; randomized controlled trial; monoclonal antibody; antibodies, monoclonal; immunotherapy; randomized controlled trials; leukemia, myeloid; lymphatic leukemia; myeloid leukemia; leukemia, lymphocytic; humans; prognosis; human; male; female
Journal Title: Current Oncology Reports
Volume: 2
Issue: 2
ISSN: 1523-3790
Publisher: Springer  
Date Published: 2000-04-01
Start Page: 114
End Page: 122
Language: English
PUBMED: 11122832
PROVIDER: scopus
DOI: 10.1007/s11912-000-0082-0
DOI/URL:
Notes: Export Date: 18 November 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joseph G Jurcic
    134 Jurcic